Skip to main content

Table 3 Self-rated health status and health utility as measured by the EQ-5D-5L by patient group

From: Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage

  Group 1 Group 2 Group 3 Between-group differences
Fisher p value
Utility weighted by the England tariff 0.809 (0.170) (n = 86) 0.818 (0.181) (n = 108) 0.695 (0.262) (n = 97) < 0.001
Visual analogue scale 72.74 (18.39) (n = 89) 77.01 (17.53) (n = 108) 65.82 (22.86) (n = 99) < 0.001
  1. Higher scores reflect higher levels of HRQoL. n, numbers shown where data were not available for all patients. See Additional file 1: Table S5 for index values estimated using the UK crosswalk tariff